We're using ML to develop a blood-based screening test for colorectal cancer, the second-most-deadly cancer (after lung). Over 50,000 people die every year in the US from this, because they don't find out they have it until too late.
Unlike drugs, diagnostics require only a single large FDA study, which is starting now. We closed a $165M series B to pay for that. That included return participation from A16z and GV, along with Roche, Kaiser, and the American Cancer Society. The office is onsite at Verily and includes Alphabet amenities.
I manage the infrastructure engineering team, but we're hiring for a number of roles, many of which do not require any bio background. Check out https://www.freenome.com/careers or email me directly at [email protected].
We're using ML to develop a blood-based screening test for colorectal cancer, the second-most-deadly cancer (after lung). Over 50,000 people die every year in the US from this, because they don't find out they have it until too late.
https://techcrunch.com/2019/07/24/with-160-million-in-new-fu... https://bmccancer.biomedcentral.com/articles/10.1186/s12885-...
Unlike drugs, diagnostics require only a single large FDA study, which is starting now. We closed a $165M series B to pay for that. That included return participation from A16z and GV, along with Roche, Kaiser, and the American Cancer Society. The office is onsite at Verily and includes Alphabet amenities.
I manage the infrastructure engineering team, but we're hiring for a number of roles, many of which do not require any bio background. Check out https://www.freenome.com/careers or email me directly at [email protected].